Courtagen, Alliance Global Sign Distribution Agreement to Help Clinicians in Emerging Markets

Courtagen Life Sciences Inc. announced that it entered into an exclusive strategic distribution agreement with Alliance Global Group. The agreement is aimed at helping clinicians working in up and coming markets identify and deal with a variety of genetic disorders.

As quoted in the press release:

Courtagen’s test menu currently offers clinical tests for mitochondrial disorders (mtSEEK™ and nucSEEK™) and a newly released panel for epilepsy and seizure (epiSEEK™). Courtagen plans to add a number of key tests for other important neurological disorders.

Courtagen’s CLIA Laboratory genetic tests use next generation sequencing (NGS) technology, propriety
bioinformatics platform, ZiPhyr™ and state of the art analytic capabilities to accurately sequence patient’s DNA and translate the sequence data into highly useful, clinically relevant information for physicians. Additionally, Courtagen’s protein diagnostics division offers decentralized testing of protein biomarker to simplify pre-clinical and clinical trial protocols.

Click here to read the full Courtagen Life Sciences Inc. press release.